On 22 July 2021, SOPHiA GENETICS SA, a Swiss healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research, priced its USD 234 million IPO, consisting of an offering of 13,000,000 ordinary shares at a price of USD 18.00 per share. The ordinary shares have been approved for listing on the Nasdaq Global Select Market under the symbols “SOPH”, and trading began on 23 July 2021. The offering closed on 27 July 2021. J.P. Morgan, Morgan Stanley, Cowen and Credit Suisse acted as joint book-running manager for the initial public offering.